Shanghai Securities News China Securities Network News (reporter Confucius Ziyuan) Harbin Pharmaceutical Co., Ltd. announced that the company's branch Harbin Pharmaceutical Group Pharmaceutical General Factory received the "Notice of Approval of Drug Supplement application" issued by the State Drug Administration on two specifications of cefazolin sodium for injection, and the drugs of the two specifications passed the consistency evaluation of the quality and efficacy of generic drugs. Cefazolin is a first-generation cephalosporin, and the antibacterial spectrum is mainly of staphylococcus, streptococcus, Streptococcus pneumoniae, Escherichia coli, Klebsiella pneumoniae, Proteus and other bacteria that are sensitive to cefazolin. At present, there are 3 specifications and 135 cefazolin sodium production approvals for injection in China.
![Cefazolin sodium for injection of Harbin Pharmaceutical Co., Ltd. passed the consistency evaluation of generic drugs[fig]](data:image/gif;base64,R0lGODlhAQABAIAAAP///wAAACwAAAAAAQABAAACAkQBADs=)